Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boryung Pharmaceutical Co., Ltd
With
Covance
BR-A-657 20, 50, 120, 240, 360, 480mg or placebo were administered once to healthy male subjects.
Pharmacokinetic and Pharmacodynamic(PK/PD) parameters were monitored at pre-specified times from each subjects.
PK parameters: Area Under the Curve(AUC), Cmax, half-life, etc. PD parameters: Aldosterone, Plasma renin activity, Angiotensin I, Angiotensin II Adverse events are reported.
Age
18–55
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
male of 18-55 years old
Body Mass Index(BMI) 19-29kg/m2
subjects in good health
subjects with written informed consent
You may not be if
subjects with multiple drug allergy or allergy to Angiotensin Receptor Blocker(ARB)
subjects with medication that affect drug absorption or elimination within 30days.
subjects with orthostatic hypotension of \>20mmHg decrease of Systolic Blood Pressure(SBP)
subjects with history of neurologic, liver, renal, gastrointestinal, cardiovascular, psychological or other major disorder